作者
Youri Hoogstrate, Santoesha A Ghisai, Maurice de Wit, Iris de Heer, Kaspar Draaisma, Job van Riet, Harmen JG van de Werken, Vincent Bours, Jan Buter, Isabelle Vanden Bempt, Marica Eoli, Enrico Franceschi, Jean-Sebastien Frenel, Thierry Gorlia, Monique C Hanse, Ann Hoeben, Melissa Kerkhof, Johan M Kros, Sieger Leenstra, Giuseppe Lombardi, Slávka Lukacova, Pierre A Robe, Juan M Sepulveda, Walter Taal, Martin Taphoorn, René M Vernhout, Annemiek ME Walenkamp, Colin Watts, Michael Weller, Filip YF de Vos, Guido W Jenster, Martin van den Bent, Pim J French
发表日期
2022/3/1
期刊
Neuro-oncology
卷号
24
期号
3
页码范围
429-441
出版商
Oxford University Press
简介
Background
EGFR is among the genes most frequently altered in glioblastoma, with exons 2-7 deletions (EGFRvIII) being among its most common genomic mutations. There are conflicting reports about its prognostic role and it remains unclear whether and how it differs in signaling compared with wildtype EGFR.
Methods
To better understand the oncogenic role of EGFRvIII, we leveraged 4 large datasets into 1 large glioblastoma transcriptome dataset (n = 741) alongside 81 whole-genome samples from 2 datasets.
Results
The EGFRvIII/EGFR expression ratios differ strongly between tumors and range from 1% to 95%. Interestingly, the slope of relative EGFRvIII expression is near-linear, which argues against a more positive selection pressure than EGFR wildtype. An absence of selection pressure is also suggested by the similar survival between …
学术搜索中的文章
Y Hoogstrate, SA Ghisai, M de Wit, I de Heer… - Neuro-oncology, 2022